Compare Cognizant Technology Solutions Corp (CTSH) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Citius Pharmaceuticals Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.25 (market cap $27.03B), while Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M). The key difference: Cognizant Technology Solutions Corp is far larger — about 1984.6× Citius Pharmaceuticals Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Citius Pharmaceuticals Inc for 17 Days on average.
| CTSH | CTXR | |
|---|---|---|
Market Cap | $27.03B | $13.62M |
Volume | 9,883,888 | 132,438 |
Sector | Technology | Health |
52-Week High | $86.70 | $1.82 |
52-Week Low | $38.73 | $0.48 |
Typical Hold Time | 57 Days | 17 Days |
Enterprise Value | $28.08B | $3.79M |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.20, up 3.73% today, with a bullish technical signal from moving averages and support at $56. The stock shows solid fundamentals with a P/E of 12.88, net income margin of 10.26%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven initiatives and strong employer recognition, supporting positive sentiment.
CTSH presents a favorable risk-reward profile with a consensus price target of $64.25 offering ~8.5% upside. Key opportunities include AI integration and stable cash flow, while risks involve IT spending pressures and competitive threats. Analyst consensus is balanced between Buy and Hold ratings, reflecting cautious optimism amid industry headwinds.
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
